Home /

Overcoming diagnostic challenges in ATTR-CM

Overcoming diagnostic challenges in ATTR-CM

How can AI help to detect transthyretin amyloid cardiomyopathy (ATTR-CM) earlier?

Severely underdiagnosed for decades

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease that has been severely underrecognized and underdiagnosed for decades. Up to 10 – 15% of older adults with heart failure may have ATTR-CM as an underlying cause1. Underrecognition of this disease leads physicians to treat for traditional heart failure without addressing the underlying amyloidosis.

Due to overlapping symptoms with heart failure, ATTR-CM is often not diagnosed until it has caused irreversible damage. Unless physicians are specifically looking for the disease, signs of amyloidosis can go unnoticed with conventional diagnostic approaches using ECG and echocardiogram.

Early detection of ATTR-CM is the key to preventing progressive disease and improving patient outcomes and quality of life.

Using AI to detect ATTR-CM and streamline the patient journey to therapy

AI algorithms trained on large datasets of ECG and echocardiogram tests can detect subtle patterns associated with ATTR-CM that the human eye might miss2. Such algorithms can lead to early detection of ATTR-CM, even before significant symptoms appear, prompting appropriate workup and treatment by clinicians.

AI-powered disease detection and care coordination is being used to detect cardiovascular diseases earlier and direct patients to the right specialist.

Viz Cardio Suite advances cardiac disease management and streamlines access to appropriate treatments:

 • AI-powered, FDA-cleared algorithms
 • Imaging viewers (ECG, echo, MRI)
 • EHR integration (Epic, Cerner, Meditech)
 • Care team communication tools

Case Study
Viz HCM, supported by Bristol Myers Squibb, is being used in clinical research to automatically analyze ECGs in real-time using AI and detect signals associated with HCM. It notifies clinicians on their Viz mobile app. Care teams can view ECGs and analyze results immediately. The patient can then receive follow-up diagnostic tests, such as an echocardiogram, which can be accessed via the Viz echocardiogram viewer, and be directed to the right specialist.


1. Ruberg F, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jun, 73 (22) 2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003
2. Goto, S., Mahara, K., Beussink-Nelson, L. et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun 12, 2726 (2021). https://doi.org/10.1038/s41467-021-22877-8

HCPs view patients with ECGs with suspected HCM findings, in green

HCPs access multiple ECGs for patients identified as having suspected HCM

HCPs view echocardiograms as well as ECGs